EUVIMEDEUVIMED entdecken
Editorial

Sudden Increases in U.S. Stimulant Prescribing: Alarming or Not?

Margaret H Sibley, Stephen V Faraone, Joel T Nigg, Craig B H Surman

Journal of Attention Disorders · 2023

DOI: 10.1177/10870547231164155 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Attention Disorders, 2023. Verfasst von Margaret H Sibley und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington School of Medicine, Seattle, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Methylphenidate. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ADHD is a neurodevelopmental disorder with a prevalence of approximately 6% in children and 3% in adults (Song et al., 2021; Willcutt, 2012). ADHD impacts public health substantially as a potentially causal precursor to many psychiatric (e.g., depression, anxiety, addiction) and somatic conditions (e.g., obesity) (Faraone et al., 2021). It is costly due to educational, vocational, and financial impairments, loss of productivity, and increased healthcare utilization (Song et al., 2021). ADHD reduces life expectancy, mostly due to suicide, accidents, and health problems, and elevates rates of incarceration and public assistance (Faraone et al., 2021). ADHD is better recognized in children than adults with long-standing disparities in care as individuals age. Effective treatments include stimulant/non-stimulant medications and behavioral approaches. A new report from the Centers for Disease Control and Prevention (CDC) documents 5 years of rising U.S. adult stimulant prescriptions, with a substantial spike from 2020 to 2021, particularly for women (Danielson et al., 2023). These trends may stem from gradual efforts (i.e., patient and provider education on adult ADHD, expanding access to ADHD care, reduction of disparity in access to health care) and relatively sudden phenomena (i.e., cognitively/ emotionally overwhelmed patients seeking treatment in the pandemic, a recent online neurodiversity movement producing viral, relatable content on ADHD, digital startups prescribing stimulants online, symptoms of long-COVID). Although seemingly rapid increases in ADHD treatmentseeking may alarm, this increase may be medically appropriate. Women and older/middle-aged adults with ADHD are historically under-identified; stimulant prescription rates became less ageand sex-dependent during the surveillance period (see Figure 1). There also may be improved care access for individuals in rural regions or who traditionally cannot afford treatment. Despite 2016 to 2021 prescribing increases in some subgroups, prescription rates came closer to ADHD’s expected prevalence in adults during this period (Song et al., 2021; Willcutt, 2012). However, we cannot be certain that all patients pescribed stimulants have ADHD or that all prescriptions represent appropriate or effective treatment. As a next step, research could evaluate the expereinces of populations with recent prescribing: who newly sought stimulant treatment? What drove them to seek care? Some evidence suggest ADHD symptoms can wax and wane— did the pandemic exacerbate ADHD in some? Why did women seek treatment at higher rates than men? Did some individuals self-identify and self-advocate for ADHD treatment due to information or advertisements seen online? If so, was ADHD the right diagnosis? Adults driving upticks in stimulant treatment may be late-identified cases, who were missed in childhood. But with rampant ADHD misinformation online (Yeung et al., 2022), and many providers untrained in proper ADHD diagnosis, they also may be misdiagnosed. It is also critical to understand whether the subpopulation with accelerated stimulant prescribing rates received optimal treatment or if alternative strategies would have better addressed their needs. It would help to know trends in behavioral treatment utilization and non-stimulant prescriptions (four are FDA-approved for ADHD in either children, adults, or both–atomoxetine, extended release viloxazine, extended release guanfacine ER, clonidine). In addition, how many stimulant prescriptions were written but not filled? Prescription fills include refills. Did more adherent subgroups (e.g., women, middle-aged adults) create an illusion of higher prescribing in these groups? Many ambiguities must be clarified to guide appropriate public health responses. Unfortunately, knowledge about and support for research on adult ADHD lags well behind childhood ADHD and other common mental disorders. As of January 2023, our reading of the National Institutes of Health (NIH) Reporter (reporter.nih.gov) lists just under $5.5 million in active funding for adult ADHD research; it reports over $42 million in funding on pediatric ADHD. Astoundingly, the NIH Reporter lists at least 10-fold greater support for depression research than ADHD research, despite only slightly higher 1164155 JADXXX10.1177/10870547231164155Journal of Attention DisordersSibley et al. editorial2023

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsMethylphenidateHumansPractice Patterns, Physicians'

Substanzen

Central Nervous System StimulantsMethylphenidate

Autor:innen und Institutionen

  • University of Washington School of Medicine, Seattle, USA.
  • SUNY Upstate Medical University, Syracuse, USA.
  • Oregon Health and Science University, Portland, USA.
  • Harvard Medical School, Boston, MA, USA.

Förderung

  • NIMH NIH HHS

Zitieren

APA

Sibley, M. H., Faraone, S. V., Nigg, J. T., & Surman, C. B. H. (2023). Sudden Increases in U.S. Stimulant Prescribing: Alarming or Not?. Journal of Attention Disorders. https://doi.org/10.1177/10870547231164155

Vancouver

Sibley MH, Faraone SV, Nigg JT, Surman CBH. Sudden Increases in U.S. Stimulant Prescribing: Alarming or Not?. Journal of Attention Disorders. 2023. doi:10.1177/10870547231164155

BibTeX
@article{Sibley2023,
  author = {Sibley, Margaret H and Faraone, Stephen V and Nigg, Joel T and Surman, Craig B H},
  title = {Sudden Increases in U.S. Stimulant Prescribing: Alarming or Not?},
  journal = {Journal of Attention Disorders},
  year = {2023},
  doi = {10.1177/10870547231164155}
}
Kostenlos starten →